Harrow (HROW) stock earns an Outperform rating at William Blair after securing U.S. rights to Byqlovi, a post-surgical pain therapy.
https://seekingalpha.com/news/4456966-harrow-stock-wins-william-blairs-new-outperform
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.